Trial
NCT02975349
A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Relapsing-remitting Multiple Sclerosis
Intervention
Evobrutinib
Why stopped
Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-14